The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC).
F. F. Kabbinavar
No relevant relationships to disclose
S. Srinivas
No relevant relationships to disclose
R. J. Hauke
Research Funding - AVEO; Pfizer
R. J. Amato
No relevant relationships to disclose
W. B. Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. M. Cotreau
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
A. L. Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. N. Fishman
Consultant or Advisory Role - Altor BioScience; Bayer; Eisai; Genentech; Novartis; Pfizer; Prometheus; Wyeth
Honoraria - Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Wyeth
Research Funding - Altor BioScience; Amgen; AVEO; Bayer; FDA; Onyx; Pfizer